Active, Not Recruiting
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
NCT06452771
- Conditions
- Healthy Volunteers With Hyperlipidemia
- Locations
-
- New Zealand Clinical Research Christchurch, Canterbury, New Zealand